Minaprine

Source: Wikipedia, the free encyclopedia.
Minaprine
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • BR: Class C1 (Other controlled substances)[1]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life2-2.5 hours
Identifiers
  • 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine
JSmol)
  • CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3
 ☒NcheckY (what is this?)  (verify)

Minaprine (

withdrawn from the market in 1996 because it caused convulsions.[3]

A study found that it acts as a

reversible inhibitor of MAO-A (RIMA) in rats.[4] It has also been found to weakly inhibit acetylcholinesterase in rat brain (striatum) homogenates.[5]

It has demonstrated significant antibiotic activity against M. chelonae and M. abscessus in tests with antibiotic resistant bacteria.[6]

Minaprine is a member of

antiparkinson drug.[7]

References

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ "Minaprine - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 2023-12-14.
  3. S2CID 73036562
    .
  4. PMID 3954800
    .
  5. PMID 10052979
    .
  6. PMID 21486854
    .
  7. ^ PubChem. "Minaprine". pubchem.ncbi.nlm.nih.gov. Retrieved 2023-12-14.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Minaprine&oldid=1190332960"